
Beyond Weight Change: What the SELECT Trial Measured About Semaglutide
Understanding a cardiovascular outcome trial requires more than reading a weight-loss headline. Here is how the 2023 SELECT publication framed its question.
Read articleCompany updates, practical sourcing guides and a closer look at peptide supply.
4 articles

Understanding a cardiovascular outcome trial requires more than reading a weight-loss headline. Here is how the 2023 SELECT publication framed its question.
Read article
From the 2015 discovery paper to later cell-envelope research, teixobactin illustrates why antimicrobial activity and resistance claims need careful context.
Read article
A research retrospective on the triple-agonist concept, from discovery work to the 2023 phase 2 obesity trial, with clear limits on interpretation.
Read article
A focused reading of the 2021 and 2022 tirzepatide trials: why study population, comparator and endpoints matter as much as the headline result.
Read article